According to a report,” Microbiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region, And Segment Forecasts, 2018 – 2025″,“, published by Grand View Research, Inc.The microbiome therapeutics market is expected to reach USD 433.5 million by 2025. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.
The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.
Key Takeaways from the report:
-
Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome
-
Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT
-
No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.
-
It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline
-
C. difficile dominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period
-
North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities
-
Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China
-
Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome
-
High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players
U.S. Microbiome therapeutics market, by application, 2014 – 2025 (USD Million)
Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.
Application Highlights
Microbiome therapeutics find wide applications in various fields, some of which are C. difficile infections, Crohn’s disease, Inflammatory Bowel Disease (IBD), and diabetes. Amongst all, C. difficile held the largest market share of over 40.0% in 2015, which can be solely due to the approval of FMT for use in the treatment of C. difficile under IND approval.
On the other hand, Crohn’s disease is expected to be the fastest growing application for microbiome therapeutics. More than 20% of drug pipeline consists of therapies for the treatment of Crohn’s disease. Other applications, such as treatment of lactose intolerance, are estimated to witness potential growth over the forecast period with the commercialization of drugs such as RP-G28 after 2019.
Ask Our Industry Expert for more details on report – www.grandviewresearch.com/inquiry/3401/ibb
Regional Outlook
North America dominated the regional market with revenue generation of over USD 5.0 million in 2015. Highly established research facility for the development of novel therapeutics, presence of health conscious population, and rising healthcare expenditure are the major factors for dominance of the region. Moreover, local presence of key players, such as OpenBiome, in this region will help in maintaining this dominance over the forecast period.
North America is closely followed by Europe with a difference of merely 9.0% in the market share. However, Asia Pacific is estimated to witness growth with a CAGR of over 49% due to factors such as increasing economic stability, high amount of biological research initiatives in national institutes, and growing awareness among physicians regarding novel therapeutics.
U.S. Microbiome therapeutics market, by application, 2016 & 2025 (USD Million)
Grand View Research has segmented the microbiome therapeutics market on the basis of type and application:
Type Outlook (Market Revenue in USD Million, 2014 – 2025)
-
FMT
-
Microbiome Drugs
Application Outlook (Market Revenue in USD Million, 2014 – 2025)
-
C. difficile
-
Crohn’s disease
-
Inflammatory Bowel Disease
-
Diabetes
-
Others
Regional Outlook (Market Revenue in USD Million, 2014 – 2025)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
UK
-
Germany
-
-
Asia Pacific
-
Japan
-
China
-
-
Latin America
-
Brazil
-
Mexico
-
-
Middle East and Africa
-
South Africa
Browse Related Report:
Aminoglycosides Market – Rising incidence of tuberculosis is expected to fuel demand for aminoglycosides market , especially in low-income countries where the incidence is alarmingly high and there is a need for TB drug regimens
Browse Latest Research Insight:
The Market Outlook For Robotic Surgery : Robotic-assisted surgery in orthopedicsis believed to have the ability to transform the orthopedic surgery through potential benefits including improved positioning, alignment, and miniaturization.
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/microbiome-therapeutics-market